Brenda Sandburg quoted AGG Partner Alan G. Minsk in an article titled “GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud” that she wrote for the November 1, 2010, edition of The Pink Sheet. The article discusses GlaxoSmithKline’s $750 million settlement with the Department of Justice (DoJ), a case that raises the question of whether good manufacturing practice violations will increase the number of whistleblower suits in the healthcare industry. Mr. Minsk says that receiving a Form 483 of inspectional observations or a warning letter from the Food and Drug Administration (FDA) will not always be followed by a False Claims Act suit, but if a company receives several warning letters, is cited for systemic problems or failure to take corrective action, or is subject to a consent decree, then the government may look at this option. Please visit The Pink Sheet for more information (subscription required to view full article).